Medscint lance HYPERSCINT® QA, un outil de contrôle qualité de nouvelle génération pour la radiothérapie

Medscint Launches HYPERSCINT® QA : A Next-Generation QA Tool for Radiotherapy

Québec, Canada – July 31, 2025 — Medscint, a leader in optical dosimetry innovation, announces the successful introduction of its solution HYPERSCINT® QA at the 2025 American Association of Physicists in Medicine (AAPM) Annual Meeting in Washington, D.C. Designed for clinical physicists seeking to modernize their quality assurance toolbox, this new medical device brings cutting-edge performance and workflow simplicity to the forefront of radiotherapy quality assurance (QA) procedures.

Your Next-Gen Clinical Quality Assurance Tool is Here!

After years of rigorous R&D, clinical collaborations, and extensive quality testing; HYPERSCINT® QA is now available to medical physics teams across the United States.

“With HYPERSCINT® QA, we’re delivering a flexible, non-perturbing, and easy-to-use system that meets the precision needs of today’s radiotherapy physicists,” said Dr. François Therriault-Proulx, President, CEO and co-founder of Medscint. “This launch reflects the dedication of our team and partners who have shaped the technology with rigor and passion.”

HYPERSCINT® QA leverages Medscint’s unique hyperspectral plastic scintillator technology to offer:

  • Better level of confidence in small field dosimetry
  • Simplified End-to-End QA workflows
  • Real-time, multi-point capabilities with water-equivalent response

This makes the HYPERSCINT® QA a unique asset in the clinical physicist’s QA toolbox, delivering cutting-edge performance and workflow simplicity for a wide range of applications, including small field – and non-standard fields – dosimetry to end-to-end QA of SRS and radiosurgery plans, whether targeting single or multiple lesions simultaneously.

Powered by Proven Scintillation Innovation

Already trusted by medical physicists and researchers at more than 50 leading institutions worldwide, Medscint solutions and technology are now ready to support daily clinical operations.

Media Contact

Jonathan Turcotte, ing. MBA | CMO and Cofounder of Medscint
info@medscint.com | 1-888-901-6521

About Medscint

Founded in 2018, Medscint develops innovative solutions to solve modern radiotherapy quality assurance challenges. Its unique hyperspectral scintillation technology is designed to enable accurate and real-time dose measurements at multiple points simultaneously. Medscint HYPERSCINT® solutions are now used across 15 countries by leading medical physics groups.